Novartis Finds All-Important Head Of Oncology Business At Pfizer
Novartis has tempted Liz Barrett away from Pfizer to become CEO of Novartis Oncology, but the appointment of a new global drug development head at the Swiss multinational has yet to be announced.
You may also be interested in...
The CDK4/6 inhibitor is Pfizer's key growth driver, generating sales of $3.1bn in 2017, but international sales declined in Q4 due to a pricing adjustment. Pfizer sought to assure investors the franchise remains on track.
Leadership changes at Pfizer, immuno-oncology combination updates from Merck and Roche, and the potential for Novo Nordisk to make a new offer for Ablynx – plus other highlights from upcoming biopharma earnings calls.
Hudson has gained his footing running Novartis' pharma business. Now, he's preparing to launch seven new drugs by 2020 while growing Cosentyx, Entresto and other in-line products.